Type 2 Diabetes – Tradjenta (linagliptin) gets FDA approval » (700 hits)
(Best Syndication News) - A new prescription medication Tradjenta (linagliptin) has gained the US Food and Drug Administration's (FDA) approval for the treatment of adult Type 2 diabetes. Tradjenta can be used alone or with other treatments to help lower blood glucose levels. Boehringer Ingelheim Pharmaceuticals Inc. are the marketers of Tradjenta.
The way Tradjenta helps to improve blood glucose levels is by blocking the enzyme dipeptidyl peptidase-4 or DPP-4. This allows hormones levels that stimulate the release of insulin to increase after a meal and thereby reducing blood glucose levels. There were eight double-blind, placebo-controlled clinical studies conducted that involved around 3,800 Type 2 diabetes patients. The results showed better blood glucose control compared to those taking a placebo.
Also there were studies conducted with stand-alone treatment with only Tradjenta and combined treatments of Tradjenta with either metformin, glimepiride, and pioglitazone. Research was also conducted with Tradjenta along with insulin treatments. Tradjenta is not a treatment for Type 1 diabetes and for those that have diabetic ketoacidosis which is increased levels of ketones found in either the blood or urine. Common side effects of Tradjenta was upper respiratory infection, stuffy or runny nose, sore throat, muscle pain, and headache. The medication will included a FDA-approved Patient Package Insert with an explanation of Tradjenta's uses and risks.
